Effect of transcranial direct current stimulation on cognitive function and quality of life in patients with Parkinson's disease: a meta-analysis
10.3969/j.issn.1006-9771.2024.02.007
- VernacularTitle:经颅直流电刺激对帕金森病患者认知功能和生活质量影响的Meta分析
- Author:
Mingchen WANG
1
;
Wenyu ZHANG
1
;
Xianzuo ZHANG
2
;
Wanli ZANG
3
Author Information
1. First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Ji'nan, Shandong 250014, China
2. Department of Orthopedics, First Affiliated Hospital, University of Science and Technology of China, Hefei, Anhui 230026, China
3. Graduate School, Harbin Sport University, Harbin, Heilongjiang 150008, China
- Publication Type:Journal Article
- Keywords:
Parkinson's disease;
cognitive impairment;
transcranial direct current stimulation;
meta-analysis
- From:
Chinese Journal of Rehabilitation Theory and Practice
2024;30(2):183-188
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the effect of transcranial direct current stimulation (tDCS) on the cognitive function and quality of life in patients with Parkinson's disease. MethodsRandomized controlled trials (RCTs) on tDCS for Parkinson's disease were searched in PubMed, Web of Science, Embase, Cochrane Library, CNKI, CBM, VIP and Wanfang Data from the inception to September, 2023. Control group was administered standard Parkinson's medications or placebo, physical therapy, and cognitive rehabilitation, while treatment group received tDCS additionally. The quality of the researches was evaluated using the Cochrane Risk of Bias Tool. Data synthesis and analysis were performed using RevMan 5.4 and Stata 17.0, with heterogeneity and sensitivity analyses. ResultsEight articles were included. tDCS significantly improved the scores of Montreal Cognitive Assessment (MD = 2.00, 95%CI 1.13 to 2.87, P < 0.001). However, there was no significant difference in the scores of Parkinson's Disease Questionnaire (MD = 0.73, 95%CI -5.78 to 7.23, P = 0.830), Beck Depression Inventory-Ⅱ(MD = -0.77, 95%CI -7.14 to 5.60, P = 0.810), and Unified Parkinson Disease Rating Scale-Ⅲ (MD = 1.60, 95%CI -0.77 to 3.97, P = 0.190). ConclusiontDCS may improve cognitive function of patients with Parkinson's disease.
